Dr Vidya Perera is a distinguished pharmaceutical executive with a profound expertise in clinical pharmacology, pharmacometrics, and translational medicine with a key focus on Cardiovascular medicines. Vidya's career is marked by a commitment to advancing drug development through innovative strategies in clinical trials.
Dr Perera began his journey in the pharmaceutical industry with a Ph.D. in Clinical Pharmacy and Drug Development from The University of Sydney, followed by a B.S. in Pharmacology and Statistics. Dr Perera has participated in development and optimization of key therapies in the cardiovascular arena including Milvexian, Apixaban and Mavacamten with over 45 peer reviewed manuscripts.
Currently, Dr Perera serves as the Vice President and Global Head of Early Clinical Development for Cardiovascular, Renal, and Immunology (CVRI) at Bayer Pharma, starting in June 2024. Outside of work he is an avid rugby league fan and foodie having lived in several countries.
